Expressive

rs1065356 (MPIG6B/LY6G6C): Substance Use Variant

Key takeaways

  • rs1065356, near MPIG6B and LY6G6C, was flagged in a multi-trait genome-wide study combining opioid, cannabis, alcohol, and smoking data.
  • This variant reduces LY6G5C gene expression in brain reward regions including the putamen, caudate, and nucleus accumbens.
  • The expression reduction also appears in whole blood, skeletal muscle, skin, and subcutaneous fat - an unusually broad tissue footprint.
  • The multi-trait analysis method used here boosts statistical power by pooling related traits, so findings should be treated as preliminary until replicated.

Key takeaways

  • rs1065356, near the MPIG6B and LY6G6C genes, was flagged in a multi-trait genome-wide study combining opioid, cannabis, alcohol, and smoking-related data.
  • In the brain, this variant is linked to reduced activity of the neighboring LY6G5C gene in reward-related regions: the putamen, caudate, nucleus accumbens, and cortex.
  • The expression reduction extends beyond the brain to whole blood, skeletal muscle, skin, and subcutaneous fat, indicating an unusually broad tissue footprint.
  • The multi-trait analysis method is designed to detect signals missed by single-trait studies, so these findings should be viewed as preliminary until independently replicated.

What the research says A multi-trait analysis of GWAS (MTAG) - a method that boosts discovery power by jointly analyzing genetically correlated traits - combined summary statistics from opioid use disorder (OUD), cannabis use disorder (CUD), alcohol use disorder (AUD), and smoking initiation in European-ancestry individuals, identifying genome-wide significant loci totaling 36 for OUD, 60 for CUD, 52 for AUD, and 144 for smoking initiation, with rs1065356 at the MPIG6B/LY6G6C locus among those identified. Separately, expression-quantitative trait locus (eQTL) data from GTEx v11 - a resource that measures how a genetic variant influences nearby gene activity - shows the alternate allele at this position consistently reduces expression of LY6G5C (a neighboring gene in the same chromosomal cluster) across eight tissue types GTEx Portal.

Reported associations

  • Substance use traits (multi-trait GWAS): The locus was identified as genome-wide significant through MTAG combining four substance use phenotypes in European-ancestry individuals; per-trait effect sizes for this specific variant were not available in the provided study text.
  • LY6G5C expression in brain basal ganglia: The alternate allele reduces LY6G5C expression in the putamen (slope -0.86, p=3.6e-23), caudate (slope -0.81, p=9.6e-24), nucleus accumbens (slope -0.70, p=4.3e-24), and cortex (slope -0.75, p=5.7e-22) GTEx Portal.
  • LY6G5C expression in peripheral tissues: Reduced expression is also observed in sun-exposed skin (slope -0.56, p=2.9e-35), whole blood (slope -0.55, p=4.4e-55), skeletal muscle (slope -0.53, p=1.6e-38), and subcutaneous adipose tissue (slope -0.51, p=5.9e-33) GTEx Portal.

Evidence quality The substance use associations come from an MTAG study drawing on the Yale-Penn cohort (5,692 European-ancestry and 4,918 African-ancestry individuals) and the Penn Medicine BioBank (29,054 European-ancestry and 10,265 African-ancestry individuals). MTAG pools signals from correlated traits to boost discovery, but associations identified through this method require replication in independent samples before being considered firmly established; the provided study text did not include per-variant effect sizes or replication data specific to rs1065356. The eQTL signals are more robustly supported: GTEx v11 data across 953 donors shows consistent reduced LY6G5C expression with p-values as low as 4.4e-55 in whole blood and 9.6e-24 in the caudate GTEx Portal. No conflicting findings were present in the provided materials.

Tissue-specific expression effects

  • LY6G5C: The alternate allele reduces expression of this gene across all eight tissues examined, with the largest effects in brain basal ganglia structures - putamen, caudate, and nucleus accumbens - that are central to reward and motivation, along with the cortex; additional reductions appear in whole blood, skeletal muscle, subcutaneous adipose tissue, and skin GTEx Portal.

Lifestyle considerations No lifestyle considerations on file for this variant.

Frequently asked questions

What is rs1065356 and which genes is it near?

rs1065356 is a genetic variant located near the MPIG6B and LY6G6C genes. It was identified in a genome-wide association study that combined data from multiple substance use disorders to increase statistical power.

Is rs1065356 linked to addiction or substance use disorders?

A multi-trait genome-wide study flagged rs1065356 as genome-wide significant when jointly analyzing opioid, cannabis, alcohol, and smoking-related traits. This pooling method improves detection sensitivity, but findings require replication in independent samples to be considered confirmed.

What does rs1065356 do to LY6G5C gene expression in the brain?

According to GTEx expression data, the alternate allele at rs1065356 is associated with reduced LY6G5C activity in brain regions involved in reward and motivation: the putamen, caudate, nucleus accumbens, and cortex. The same reduction appears in blood, muscle, and skin.

What is LY6G5C and why is its expression relevant here?

LY6G5C is a gene neighboring LY6G6C and MPIG6B whose role in brain reward circuits is not yet fully characterized. Its consistent reduction in expression across multiple tissues, including key brain reward regions, makes it a biological candidate for further study in the context of this locus.

How reliable is the evidence linking rs1065356 to substance use traits?

The association was found using MTAG, a method that combines signals from genetically related traits to boost discovery, in a study covering tens of thousands of individuals from two cohorts. This qualifies as genome-wide significant evidence, but replication in independent cohorts would be needed to strengthen confidence.